JDP Therapeutics Inc.
This article was originally published in Start Up
JDP Therapeutics Inc. is working to reformulate an off-patent oral drug into an injectable form that will treat the peripheral, non-life-threatening symptoms of acute allergic reactions to substances such as peanuts and seafood. The benefit envisioned? Fewer side effects than the IV Benadryl currently given to relieve body swelling and itching.
You may also be interested in...
This Month's Profile Group: Cartilage Repair: Opportunities In Motion-Preserving Orthopedics, features profiles of Articulinx, Carticept Medical and Orthox. Plus these Start-Ups Across Health Care: Ellipse Technologies, JDP Therapeutics, NuMe Health and SironRX Therapeutics.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.